UniProtKB/Swiss-Prot P51787 : Variant p.Gly314Ser
Potassium voltage-gated channel subfamily KQT member 1
Gene: KCNQ1
Feedback ?
Variant information
Variant position:
314
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Glycine (G) to Serine (S) at position 314 (G314S, p.Gly314Ser).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from glycine (G) to small size and polar (S)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In LQT1.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
314
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
676
The length of the canonical sequence.
Location on the sequence:
VEFGSYADALWWGVVTVTTI
G YGDKVPQTWVGKTIASCFSV
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human VEFGSYADALWWGVVTVTTIG YGDKVPQTWVGKTIASCFSV
Mouse IEFGSYADALWWGVVTVTTIG YGDKVPQTWVGKTIASCFSV
Rat IEFGSYADALWWGVVTVTTIG YGDKVPQTWVGKTIASCFSV
Pig VEFGSYADALWWGVVTVTTIG YGDKVPQTWVGKTIASCFSV
Rabbit VEFGSYADALWWGVVTVTTIG YGDKVPQTWVGKTIASCFSV
Xenopus laevis YQFGSYADALWWGVVTVTTIG YGDKVPQTWIGKTIASCFSV
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 676
Potassium voltage-gated channel subfamily KQT member 1
Intramembrane
300 – 320
Pore-forming; Name=Segment H5
Mutagenesis
324 – 324
V -> L. Has a voltage-gated potassium channel activity. Inhibition of voltage-gated potassium channel activity by KCNE4.
Mutagenesis
326 – 326
K -> R. Has a voltage-gated potassium channel activity. Disrupts KCNE4-mediated voltage-gated potassium channel activity inhibition.
Mutagenesis
327 – 327
T -> V. Has a voltage-gated potassium channel activity. Disrupts KCNE4-mediated voltage-gated potassium channel activity inhibition.
Mutagenesis
328 – 328
I -> L. Has a voltage-gated potassium channel activity. Inhibition of voltage-gated potassium channel activity by KCNE4.
Literature citations
Genomic organization and mutational analysis of KVLQT1, a gene responsible for familial long QT syndrome.
Itoh T.; Tanaka T.; Nagai R.; Kikuchi K.; Ogawa S.; Okada S.; Yamagata S.; Yano K.; Yazaki Y.; Nakamura Y.;
Hum. Genet. 103:290-294(1998)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 2); VARIANTS LQT1 ASN-242; HIS-250; SER-314 AND MET-587; VARIANT SER-643;
KVLQT1 mutations in three families with familial or sporadic long QT syndrome.
Russell M.W.; Dick M. II; Collins F.S.; Brody L.C.;
Hum. Mol. Genet. 5:1319-1324(1996)
Cited for: VARIANTS LQT1 SER-314 AND VAL-341;
KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome.
Donger C.; Denjoy I.; Berthet M.; Neyroud N.; Cruaud C.; Bennaceur M.; Chivoret G.; Schwartz K.; Coumel P.; Guicheney P.;
Circulation 96:2778-2781(1997)
Cited for: VARIANTS LQT1 ARG-168; CYS-174; GLN-190; MET-254; LYS-261; ASP-269; ARG-309; SER-314; SER-315; ALA-320; ARG-325; VAL-341; PHE-342; VAL-344; THR-371 AND CYS-555;
Genomic structure of three long QT syndrome genes: KVLQT1, HERG, and KCNE1.
Splawski I.; Shen J.; Timothy K.W.; Vincent G.M.; Lehmann M.H.; Keating M.T.;
Genomics 51:86-97(1998)
Cited for: VARIANTS LQT1 ARG-168; SER-314; CYS-315; ASN-318; PRO-353 AND TRP-366;
Novel KCNQ1 and HERG missense mutations in Dutch long-QT families.
Jongbloed R.J.E.; Wilde A.A.M.; Geelen J.L.M.C.; Doevendans P.; Schaap C.; van Langen I.; van Tintelen J.P.; Cobben J.M.; Beaufort-Krol G.C.M.; Geraedts J.P.M.; Smeets H.J.M.;
Hum. Mutat. 13:301-310(1999)
Cited for: VARIANTS LQT1 SER-184; ARG-189; SER-314; SER-315; ARG-345; PRO-373 AND ARG-392;
Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing.
Tester D.J.; Will M.L.; Haglund C.M.; Ackerman M.J.;
Heart Rhythm 2:507-517(2005)
Cited for: VARIANTS LQT1 71-ALA--PRO-73 DEL; THR-73; GLY-115; TYR-122; ILE-133; PHE-136; LYS-160; ARG-168; CYS-174; GLN-190; PHE-204; LEU-225; ASN-235; ASN-242; CYS-243; MET-254; 254-VAL--PHE-256 DEL; CYS-259; LEU-259; ASP-261; PRO-266; SER-269; ASP-269; PHE-273; ARG-273; SER-276 DEL; LEU-277; HIS-278; LYS-290; ASP-292; CYS-293; VAL-302; ARG-304; SER-305; ILE-312; SER-314; ARG-314; ASP-314; CYS-315; ARG-316; ALA-322; PHE-339 DEL; VAL-341; SER-343; GLU-344; VAL-344; GLU-345; TRP-349; PRO-353; ARG-362; TRP-366; HIS-374; SER-380; TYR-389; TRP-452; GLY-524; GLU-526; TRP-539; LEU-546; CYS-555; HIS-555; TYR-566; SER-567; ARG-568; MET-587; THR-590; HIS-591; GLN-594; MET-619 AND SER-626;
Spectrum of pathogenic mutations and associated polymorphisms in a cohort of 44 unrelated patients with long QT syndrome.
Millat G.; Chevalier P.; Restier-Miron L.; Da Costa A.; Bouvagnet P.; Kugener B.; Fayol L.; Gonzalez Armengod C.; Oddou B.; Chanavat V.; Froidefond E.; Perraudin R.; Rousson R.; Rodriguez-Lafrasse C.;
Clin. Genet. 70:214-227(2006)
Cited for: VARIANTS LQT1 CYS-231; PRO-243; CYS-259; HIS-259; PHE-273; SER-314; GLU-316; VAL-341; VAL-344 AND SER-626;
Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test.
Kapplinger J.D.; Tester D.J.; Salisbury B.A.; Carr J.L.; Harris-Kerr C.; Pollevick G.D.; Wilde A.A.; Ackerman M.J.;
Heart Rhythm 6:1297-1303(2009)
Cited for: VARIANTS LQT1 VAL-2; SER-7; THR-46; 64-PRO--PRO-70 DEL; PHE-66; THR-73; CYS-111; LEU-117; LEU-127; ILE-133; PRO-134; ALA-144; MET-153; MET-162; ARG-168; MET-172; CYS-174; HIS-174; THR-178; SER-179; HIS-184; ARG-186; GLN-190; LEU-190; TRP-195; VAL-198; ALA-199; MET-204; MET-215; MET-224; LEU-225; CYS-231; HIS-231; ASN-235; GLY-241; ASN-242; CYS-243; PRO-250; MET-254; CYS-259; LEU-259; VAL-262; PRO-266; SER-268; ASP-269; SER-269; ASP-272; PHE-273; VAL-274; LEU-277; PRO-277; GLU-280; CYS-281; PRO-282; GLY-283; ASP-292; CYS-293; GLU-302; VAL-302; PRO-303; ARG-305; SER-305; ARG-306; ILE-312; CYS-314; SER-314; CYS-315; VAL-316; SER-320; ALA-322; MET-322; ARG-325; TYR-339; GLU-341; GLY-341; VAL-341; PHE-342; LEU-343; ARG-350; SER-351; ARG-354; MET-360; ARG-362; HIS-365; GLN-366; TRP-366; HIS-374; GLY-379; LYS-385; PRO-389; THR-391 INS; TRP-397; ARG-398; GLU-446; LEU-448; TRP-451; SER-460; LEU-477; TRP-511; GLN-518; ARG-520; SER-522; GLY-524; THR-525; VAL-525; TRP-533; GLN-539; TRP-539; ILE-541; LYS-543; LEU-546; ARG-547; CYS-555; HIS-555; SER-555; GLU-557; PHE-566; PRO-566; TYR-566; THR-567; ARG-568; GLU-569; LEU-571; MET-587; ASP-589; CYS-591; HIS-591; GLN-594; PRO-594; GLU-596 DEL; LYS-596; MET-600; ASN-611; HIS-614 DEL; SER-626 AND ARG-635;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.